超越原发性HER2表达：曲妥珠单抗德鲁昔单抗在脑转移中的疗效
Beyond Primary HER2 Expression: Trastuzumab Deruxtecan's Efficacy in Brain Metastasis.
作者信息
Das Glori, Wong Stephen T C, Zhao Hong
机构信息
Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX 77030, USA.
Department of Biomedical Engineering, Texas A&M University School of Medicine, College Station, TX 77843, USA.
出版信息
Cancers (Basel). 2024 Oct 18;16(20):3525. doi: 10.3390/cancers16203525.
Abstract
This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.
摘要
本评论聚焦于2024年9月13日发表在《自然·医学》上的DESTINY-Breast12研究，该研究评估了曲妥珠单抗德鲁昔单抗（T-DXd）治疗HER2阳性晚期乳腺癌（包括伴有脑转移的患者）的疗效。我们强调T-DXd在治疗原本分类为HER2阴性或HER2低表达肿瘤的脑转移方面具有更广泛的临床潜力，这超出了其目前在乳腺癌治疗中的应用范围。T-DXd的这种扩展应用可为应对具有挑战性脑转移的患者带来新希望，满足对有效治疗方案的迫切需求。
相似文献
1
Beyond Primary HER2 Expression: Trastuzumab Deruxtecan's Efficacy in Brain Metastasis.超越原发性HER2表达：曲妥珠单抗德鲁昔单抗在脑转移中的疗效
Cancers (Basel). 2024 Oct 18;16(20):3525. doi: 10.3390/cancers16203525.
2
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.DESTINY-Breast Respond HER2-low 欧洲研究设计：T-DXd 在 HER2 低表达晚期乳腺癌患者中的应用。
Future Oncol. 2024;20(18):1237-1250. doi: 10.2217/fon-2024-0015. Epub 2024 Apr 9.
3
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.曲妥珠单抗-德曲妥珠单抗治疗既往治疗的 HER2 阳性转移性乳腺癌：DESTINY-Breast01 研究的通俗易懂摘要。
Future Oncol. 2021 Sep 1;17(26):3415-3423. doi: 10.2217/fon-2021-0427. Epub 2021 Jul 15.
4
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新在随机 DESTINY-Breast03 试验中用于 HER2 阳性转移性乳腺癌伴脑转移患者的比较。
ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24.
5
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.曲妥珠单抗-德鲁替康在乳腺癌脑转移中的临床前和临床疗效。
Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138.
6
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.曲妥珠单抗德鲁昔单抗与曲妥珠单抗恩坦辛治疗HER2阳性乳腺癌的成本效益分析。
Front Pharmacol. 2022 Sep 9;13:924126. doi: 10.3389/fphar.2022.924126. eCollection 2022.
7
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.曲妥珠单抗恩美曲妥珠单抗在 HER2 低表达三阴性乳腺癌中的应用：综述
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1061-1069. doi: 10.1080/14737140.2023.2257885. Epub 2023 Oct 26.
8
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.在 III 期 DESTINY-Breast03 研究中，接受曲妥珠单抗 deruxtecan 或曲妥珠单抗 emtansine 的 HER2 阳性转移性乳腺癌患者的患者报告结局和住院数据。
Ann Oncol. 2023 Jul;34(7):569-577. doi: 10.1016/j.annonc.2023.04.516. Epub 2023 May 12.
9
Trastuzumab deruxtecan for HER2+ advanced breast cancer.曲妥珠单抗-德曲妥珠单抗用于治疗 HER2 阳性晚期乳腺癌。
Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26.
10
Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.曲妥珠单抗-德鲁替康治疗 HER2 表达可变的乳腺癌脑膜转移患者的持久应答。
J Neurooncol. 2024 Oct;170(1):209-217. doi: 10.1007/s11060-024-04788-y. Epub 2024 Jul 29.
本文引用的文献
1
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.转移性乳腺癌内分泌治疗后使用曲妥珠单抗德卢替康
N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15.
2
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验
Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13.
3
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗既往治疗过的 HER2 低表达晚期乳腺癌伴活动性脑转移患者：DEBBRAH 试验。
ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9.
4
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.
5
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.HER2阴性乳腺癌患者中HER2表达脑转移的发生率：一项匹配病例分析。
NPJ Breast Cancer. 2023 Oct 23;9(1):86. doi: 10.1038/s41523-023-00592-5.
6
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.曲妥珠单抗-德鲁替康治疗 HER2 表达可变的转移性乳腺癌：Ⅱ期 DAISY 试验。
Nat Med. 2023 Aug;29(8):2110-2120. doi: 10.1038/s41591-023-02478-2. Epub 2023 Jul 24.
7
Heterogeneity of HER2 Expression in Circulating Tumor Cells of Patients with Breast Cancer Brain Metastases and Impact on Brain Disease Control.乳腺癌脑转移患者循环肿瘤细胞中HER2表达的异质性及其对脑部疾病控制的影响。
Cancers (Basel). 2022 Jun 24;14(13):3101. doi: 10.3390/cancers14133101.
8
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
9
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.检测乳腺癌组织中低 ERBB2 蛋白的表达。
JAMA Oncol. 2022 Apr 1;8(4):1-4. doi: 10.1001/jamaoncol.2021.7239.
10
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.帕妥珠单抗联合高剂量曲妥珠单抗治疗进展性脑转移和 HER2 阳性转移性乳腺癌患者：一项 II 期研究的主要分析。
J Clin Oncol. 2021 Aug 20;39(24):2667-2675. doi: 10.1200/JCO.20.02822. Epub 2021 May 4.
Zotero 插件